Selepressin information

Selepressin
Clinical data
Other names	H-Cys(1)-Phe-Ile-hGln-Asn-Cys(1)-Pro-Orn(iPr)-Gly-NH2
ATC code	None;
Identifiers
	IUPAC name (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-5-(propan-2-ylamino)pentan-2-yl]pyrrolidine-2-carboxamide;
CAS Number	876296-47-8;
PubChem CID	53330936;
ChemSpider	26609297;
UNII	8P2T76M0SJ;
ChEMBL	ChEMBL1817709;
CompTox Dashboard (EPA)	DTXSID90236538 ;
Chemical and physical data
Formula	C46H73N13O11S2
Molar mass	1048.29 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)Cc2ccccc2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N;
	InChI InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1; Key:JCVQBJTWWDYUFQ-MRUTUVJXSA-N;

Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which was under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.^[1]^[2]^[3]^[4]

The Phase 2b/3 adaptive trial (SEPSIS-ACT) was terminated in February 2018 for futility. The trial was halted prior to the initiation of the arm for the highest dosing regimen of 5.0 ng/kg/min.^[5]

^ Levin JI (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2.
^ Vincent JL (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2.
^ Vincent JL (2 September 2008). Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. pp. 427–. ISBN 978-3-540-77290-3.
^ Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, et al. (June 2011). "Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension". The Journal of Pharmacology and Experimental Therapeutics. 337 (3): 786–96. doi:10.1124/jpet.111.178848. PMID 21411496. S2CID 576654.
^ Clinical trial number NCT02508649 for "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial" at ClinicalTrials.gov

[Levin2014-1] Levin JI (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2.

[Vincent2012-2] Vincent JL (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2.

[Vincent2008-3] Vincent JL (2 September 2008). Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. pp. 427–. ISBN 978-3-540-77290-3.

[LaporteKohan2011-4] Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, et al. (June 2011). "Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension". The Journal of Pharmacology and Experimental Therapeutics. 337 (3): 786–96. doi:10.1124/jpet.111.178848. PMID 21411496. S2CID 576654.

[5] Clinical trial number NCT02508649 for "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial" at ClinicalTrials.gov

Selepressin information

and 23 Related for: Selepressin information

Selepressin

Vasopressin

Oxytocin

Desmopressin

Atosiban

Lithium carbonate

Tolvaptan

Terlipressin

Oxytocin receptor agonist

Vasopressin receptor

Uterotonic

Oxytocin receptor

Carbetocin

Felypressin

Vasotocin

Vasopressin receptor 1A

Lixivaptan

Vasopressin receptor antagonist

Demeclocycline

Barusiban

Epelsiban

Neurophysin II

Neurophysin I